WuXi AppTec has entered into a partnership with Qiagen to provide an integrated solution for molecular biomarker development, validation and personalized healthcare targets to their respective clients. Qiagen will provide instrumentation, training, and consumables and WuXi will provide lab services at its Shanghai campus.

WuXi will also work with Qiagen to help develop biomarkers, assay panels, personalized healthcare diagnostics, and other products that Qiagen intends to bring to market. WuXi will use Qiagen’s technologies to support drug discovery and development on behalf of their respective clients. The two companies will also co-promote each other’s services to customers.

“WuXi AppTec has long been interested in partnering with a premier international molecular biotechnology company like Qiagen to support the development of our biomarker business,” said Dr. Ge Li, chairman and chief executive officer of WuXi AppTec. “This partnership gives us access to innovative technologies and processes that will allow us to better serve our customers.”

“We are very pleased to have entered into this partnership with WuXi AppTec, a global leader in providing integrated research and development services to the pharmaceutical industry,” said Dr. Victor Shi, Qiagen’s president, Asia Pacific. “In doing so, we have created what we believe to be the first laboratory of its kind in Asia equipped with a standardized, fully integrated, automated sample and assay technology platform for drug discovery and development and molecular diagnostics in personalized healthcare and other areas. We believe that this partnership is a significant milestone in providing high-quality and complete automated solutions for the molecular biomarker testing industry.”